Last $23.68 USD
Change Today +0.57 / 2.47%
Volume 22.3K
AKBA On Other Exchanges
As of 10:54 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

akebia therapeutics inc (AKBA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/20/14 - $31.00
52 Week Low
04/9/14 - $16.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

akebia therapeutics inc (AKBA) Related Businessweek News

No Related Businessweek News Found

akebia therapeutics inc (AKBA) Details

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

24 Employees
Last Reported Date: 03/21/14
Founded in 2007

akebia therapeutics inc (AKBA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $162.0K
Chief Medical Officer
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2013.

akebia therapeutics inc (AKBA) Key Developments

Akebia Therapeutics, Inc. Announces Executive Changes

Akebia Therapeutics, Inc. announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments. Dr. Clayman is a Co-Founder of Flexion, and has served as President and Chief Executive Officer since the company's inception in 2007. Previously, Dr. Clayman served in senior management positions at Eli Lilly and Company (Lilly), most recently as Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly's early-phase development accelerator. Dr. Gowen joined Trevena in 2007 as its founding President and CEO. Prior to this position, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of 15 years.

Akebia Therapeutics, Inc.(NasdaqGM:AKBA) added to Russell 2000 Index

Akebia Therapeutics, Inc. will be added to the Russell 2000 Index.

Akebia Therapeutics, Inc.(NasdaqGM:AKBA) added to Russell 3000 Index

Akebia Therapeutics, Inc. will be added to the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBA:US $23.68 USD +0.57

AKBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBA.
View Industry Companies

Industry Analysis


Industry Average

Valuation AKBA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKEBIA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at